Phase I tolerability, pharmacokinetics and preliminary efficacy of ACH 1625 in volunteers and hepatitis C-infected patients

Trial Profile

Phase I tolerability, pharmacokinetics and preliminary efficacy of ACH 1625 in volunteers and hepatitis C-infected patients

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Apr 2011

At a glance

  • Drugs Sovaprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 03 Apr 2011 Results presented at the 46th Annual Meeting of the European Association for the Study of the Liver.
    • 15 Sep 2010 An abstract has been accepted as a late-breaking poster at the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD), according to an Achillion Pharmaceuticals media release.
    • 11 May 2010 Additional preliminary results from the phase 1b part of the trial have been reported in a Achillion Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top